Findings

What do systematic reviews say?

2,532 questions · 2,642 findings · 483 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 534 · 20.2%GRADE not reported 82 · 3.1%Very low 641 · 24.3%Low 807 · 30.5%Moderate 472 · 17.9%High 106 · 4%

Renin‐angiotensin system inhibition vs supportive treatment

Death · people IgA nephropathy

The review found no eligible studies for this question.

1 finding from 1 review

Non‐immunosuppressive treatment for IgA nephropathy 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Renin‐angiotensin system inhibition vs supportive treatment

Kidney failure · people IgA nephropathy

It is very uncertain whether renin‐angiotensin system inhibition changes kidney failure compared with other supportive care treatment (very low certainty).

1 finding from 1 review

Non‐immunosuppressive treatment for IgA nephropathy 2024 · Cochrane Headline outcomes only
RR 0.2 [0.01, 3.88]
1 study · 34 participants
Very low

Angiotensin‐converting enzyme inhibitors vs vitamin C

Serious adverse events · children with sickle cell anaemia and microalbuminuria

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Angiotensin‐converting enzyme inhibitors vs vitamin C

Mortality due to any cause · children with sickle cell anaemia and microalbuminuria

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Angiotensin‐converting enzyme inhibitors vs vitamin C

Quality of life · children with sickle cell anaemia and microalbuminuria

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Angiotensin‐converting enzyme inhibitors vs placebo

Reduction or prevention of kidney disease progression · people with sickle cell disease

1 finding from 1 review

Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Very low

Angiotensin‐converting enzyme inhibitors vs placebo

Serious adverse events · people with sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Angiotensin‐converting enzyme inhibitors vs placebo

All‐cause mortality · people with sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Angiotensin‐converting enzyme inhibitors vs placebo

Quality of life · people with sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Angiotensin‐converting enzyme inhibitors vs vitamin C

Reduction or prevention of kidney disease progression · children with sickle cell anaemia and microalbuminuria

1 finding from 1 review

Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 170 participants
Very low

Angiotensin‐converting enzyme inhibitors vs placebo

Migraine frequency Number of attacks · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 44 participants
Low

Angiotensin‐converting enzyme inhibitors vs placebo

Severity of attacks · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 34 participants
Low

Angiotensin‐converting enzyme inhibitors vs placebo

Duration of attacks · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 14 participants
Low

Angiotensin‐converting enzyme inhibitors vs placebo

QoL · primary Raynaud's phenomenon

The review found no eligible studies for this question.

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Angiotensin‐converting enzyme inhibitors vs placebo

Adverse events (4 to 6‐week · primary Raynaud's phenomenon

Angiotensin‐converting enzyme inhibitors showed no clear difference in adverse events (4 to 6‐week compared with placebo (low certainty).

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
RR 1.35 [0.67, 2.73]
3 studies · 46 participants
Low

Angiotensin‐converting enzyme inhibitors vs placebo

RCS · primary Raynaud's phenomenon

The review found no eligible studies for this question.

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Motivational interviewing intensive (MII) vs motivational interviewing (MI) to reduce alcohol consumption

Addiction Severity Index alcohol score · concurrent problem alcohol and illicit drug users

3 findings from 1 review

Psychosocial interventions to reduce alcohol consumption in concurrent problem alcohol and illicit drug users 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 163 participants
Low
Psychosocial interventions to reduce alcohol consumption in concurrent problem alcohol and illicit drug users 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 163 participants
Low
Psychosocial interventions to reduce alcohol consumption in concurrent problem alcohol and illicit drug users 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 163 participants
Low

Motivational interviewing intensive (MII) vs motivational interviewing (MI) to reduce alcohol consumption

Retention [ · concurrent problem alcohol and illicit drug users

Motivational interviewing intensive (MII) may leads to higher retention ‐ end of treatment compared with motivational interviewing (MI) to reduce alcohol consumption (low certainty).

1 finding from 1 review

Psychosocial interventions to reduce alcohol consumption in concurrent problem alcohol and illicit drug users 2018 · Cochrane Headline outcomes only
RR 17.63 [1.03, 300.48]
1 study · 163 participants
Low

Intensive discharge planning and case management vs prison only

Marijuana use · summary findings of female review

Intensive discharge planning and case management showed no clear difference in marijuana use compared with prison only (moderate certainty).

1 finding from 1 review

Interventions for female drug‐using offenders 2019 · Cochrane Headline outcomes only
RR 0.79 [0.53, 1.16]
1 study · 511 participants
Moderate

Intensive discharge planning and case management vs prison only

Hard drug use · summary findings of female review

Intensive discharge planning and case management showed no clear difference in hard drug use compared with prison only (moderate certainty).

1 finding from 1 review

Interventions for female drug‐using offenders 2019 · Cochrane Headline outcomes only
RR 1.12 [0.88, 1.43]
1 study · 511 participants
Moderate